Disease Landscape and Forecast Insights

Clarivate Epidemiology’s coverage of PV comprises epidemiological estimates of key patient populations in the major emerging pharmaceutical markets (Brazil, China, India, Mexico, Russia, South…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Pemphigus vulgaris patient population covering 171 countries and…

Clarivate Epidemiology’s coverage of Pemphigus vulgaris comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of Pemphigus vulgaris…

Clarivate Epidemiology’s coverage of PV comprises epidemiological estimates of key patient populations in the major Middle East & Africa pharmaceutical markets (Egypt, Nigeria, Saudi Arabia, and…

Clarivate Epidemiology’s coverage of PV comprises epidemiological estimates of key patient populations in the major Asia-Pacific pharmaceutical markets (Australia, Hong Kong, Indonesia, Malaysia…

Clarivate Epidemiology’s coverage of PV comprises epidemiological estimates of key patient populations in the major Americas pharmaceutical markets (Argentina, Canada, Chile, Colombia, and Peru…

Clarivate Epidemiology’s coverage of PV comprises epidemiological estimates of key patient populations in the major European pharmaceutical markets (Austria, Belgium, Czech Republic, Denmark,…

As the number of gene therapy approvals rises, novel approaches to value assessment and reimbursement schemes for these innovative, high-cost treatments are rapidly gaining importance. Developers…

This content examines the market access factors that influence the success or failure of therapies for renal anemia. It is based on primary research with U.S. nephrologists and MCO pharmacy and…

Pancreatic cancer is a difficult-to-treat malignancy, with dismal survival outcomes. First-line treatment of metastatic disease is limited to chemotherapy-based regimens such as FOLFIRINOX and…

Clarivate Epidemiology’s coverage of methicillin-resistant staphylococcus aureus (MRSA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…

The biosimilar / follow-on insulin sector of the diabetes therapy market is evolving. Eli Lilly / Boehringer Ingelheim’s Abasaglar / Basaglar was the first biosimilar / follow-on insulin glargine…